Author:
Bilquees ,Jeelani Humira,Tabasum Nahida,Pottoo Faheem Hyder
Reference84 articles.
1. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis;Aguiar;Immunotherapy,2016
2. Ahmed, N., Brawley, V., Diouf, O., Anderson, P., Hicks, J., Wang, L., … Gee, A. (2012). T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma. AACR.
3. Personalized neoantigen vaccines: A new approach to cancer immunotherapy;Aldous;Bioorganic & Medicinal Chemistry,2018
4. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome;Alsaab;Frontiers in Pharmacology,2017
5. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study;Antonia;The Lancet Oncology,2016